tocilizumab,elranatamab,siltuximab
pfizer,roche,jazz pharmaceuticals
['toci', 'siltuximab', 'magnetismm-3', 'mmsm', 'elrana ', '2019', 'tocilizumab', 'emergent ', 'rafael ', 'imab ']
 presenting on magnetismm-3 elrana ph 2 on those w/o prior bcma exposure. tcr 97%. 32% em dz. n=123. orr 61%, 28% cr. responses are durable and improve over time. 12 mo pfs 64%. mostly hematological ae. infections in 66.7% #ash2022rf #mmsm 
Chief Innovation Officer - Mayo Clinic in Arizona. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement